Purpose-The dual modality of TGFβ, both as a potent tumor suppressor and a stimulator of tumor progression, invasion, and metastasis, make it a critical target for therapeutic intervention in human cancers. The ability to perform real-time, noninvasive imaging of TGFβ-activated Smad signaling in live cells and animal models would significantly improve our understanding of the regulation of this unique signaling cascade. To advance these efforts, we developed a highly sensitive molecular imaging tool that repetitively, non-invasively and dynamically reports on TGFBR1 kinase activity.
Statement of Translational Relevance
The response of cells to TGFβ stimulation is highly contextual in cancer. Loss or mutational inactivation of genes that mediate the TGFβ pathway early in carcinogenesis is indicative of its role as a tumor suppressor. Yet, paradoxically, TGFβ also modulates processes such as cell invasion and modifications of the tumor microenvironment that are critical for metastasis and tumor establishment at distant sites. Although therapeutic agents have been developed targeting this pathway, their rational use will require a better understanding of the regulation of its signaling. In this effort, we in this paper describe the development of a reporter molecule wherein TGFβ receptor I kinase activity can be imaged dynamically and non-invasively in living subjects. We also provide preliminary results that TGFβ signaling activity is impacted by seemingly unrelated signaling cascades, providing potential explanation for the contextual differences in TGFβ downstream signaling events in cancer.
Introduction
The transforming growth factor-β (TGFβ) signaling pathway regulates growth inhibition and tumor suppression through control of cell proliferation, differentiation, apoptosis, migration, and adhesion (1) . Consequently, when the TGFβ signaling pathway is disrupted, either through genetic mutations of key signaling components or due to loss of its growth inhibition capabilities, tumorigenesis occurs. It has been demonstrated that TGFβ plays a dual role in cancer development (2, 3) . During early stages of tumorigenesis, when the tumor cells are premalignant, TGFβ suppresses cellular outgrowth whereas at later stages, following alteration of TGFβ-responsiveness and increased ligand expression, it promotes tumor progression, invasion, and metastasis. Tumor cells that have lost TGFβ-mediated tumor suppression but maintain intact components of its core signaling pathway are especially aggressive. These cells exploit TGFβ for pro-oncogenic activities: epithelial-to-mesenchymal transition (EMT), tumor invasion, mitogen production, metastatic dissemination, and immune evasion (2, 3) .
TGFβ cellular activity is mediated through a receptor serine-threonine kinase (RSK) complex.
TGFβ initiates the interaction of TGFβ Type-1 and Type-2 receptors (TGFBR1 and TGFBR2, respectively) which phosphorylate the C-terminal SXS motif of receptor-regulated Smads (R-It is necessary for Smad complex assembly and disassembly, nuclear translocation, and transcriptional activity and stability required for Smad-mediated cellular responses (4) .
Despite the importance of TGFβ-mediated Smad signaling in the progression of human cancers, methods for monitoring in vivo and in vitro Smad phosphorylation are limited. Indirect molecular imaging techniques have been developed using fluorescent-tagged proteins in the TGFβ-Smad signaling pathway to study cellular localization of Smad proteins in breast cancer cells (5, 6 ) and protein-protein interaction of critical elements of TGFβ signaling in xenopus embryogenesis (7) . More direct measures of TGFβ signaling, have been designed using a firefly luciferase reporter linked to Smad responsive elements (SBE) to measure transcription of target genes in breast cancer metastasis (8, 9) , skin wound healing (10), neurodegeneration, (11) , and response to injury (12) . These imaging methods are limited in that they do not measure the key upstream event in TGFβ signaling, the phosphorylation of R-Smads.
In this study, we developed a molecular imaging reporter for non-invasive, repetitive monitoring of TGFβ activity using the critical R-Smad phosphorylation step in the TGFβ signaling pathway.
The reporter showed higher sensitivity to changes in Smad phosphorylation than measured by conventional western analysis and provided new insight into pharmacodynamics of TGFβ inhibitor SB431542 in vivo. It was successfully adapted for high throughput screening and utilized to delineate key modulators of Smad2 signaling. The reporter demonstrates immense potential for identifying novel effectors of R-Smad phosphorylation; for validating drug-target interactions; and for studying TGFβ signaling in different metastasis models.
Materials and Methods

Construction of the Bioluminescent TGFβR reporter (BTR)
To image TGFBR1 kinase activity, we constructed a recombinant chimeric reporter (Fig. 1A, B) consisting of a 15 amino acid target peptide sequence derived from the C-terminus of Smad2 containing the SXS motif, aa 453-467, a TGFBR1 substrate (13) . The BTR reporter was constructed through fusion of the Smad2 peptide sequence and the FHA2 phospho-serinethreonine binding domain of Rad53, which were flanked by the amino-( N-Luc) and carboxyl-(C-Luc) terminal domains of the firefly luciferase reporter molecule (14) . The cloning primers were designed with a linker sequence (GlyGlyAlaGlyGly) on both ends and XbaI/XmaI precut sites. The BTR-WT was constructed using the appropriate primers (CTA GAG GAG GAA GTG GAG GGT TAA CTC AGA TGG GAT CCC CTT CAG TGC GTT GCT CAA GCA TGT CAC and CCG GGT GAC ATG CTT GAG CAA CGC ACT GAA GGG GAT CCC ATC TGA GTT AAC CCT CCA CTT CCT CCT). The mutant reporter, BTR-MUT, was generated by substituting both serines of the SXS motif with alanine using a single primer mutagenesis protocol, with minor modifications as described earlier (15) , using the following primer: CCT TCA GTG CGT TGC TCA GCC ATG GCA CCC GGG GGA GGA GCT GGA GGA TCC GGT TAT GT. All the clones were sequence verified.
Cell Culture and Transfection
The human lung carcinoma cell line A549 (American Type Culture collection, ATCC) was maintained in RPMI-1620 media supplemented with 10% heat-inactivated fetal bovine serum, NY). Cell cultures were grown in a humidified incubator at 37
• C and 5% CO 2 . Breast cancer cell line 1833 derived from MDA-MB-431 (16) was kindly provided by Dr Joan Massague and maintained in DMEM media in the same conditions mentioned above. Cell cultures were grown in a humidified incubator at 37
• C and 5% CO 2 . ATCC cell line was tested routinely for mycoplasma and purity. All ATCC lines were expanded immediately upon receipt and multiple vials of low passage cells were maintained in liquid N 2 . No vial of cells was cultured for more than 1-2 months. Stable cell lines were developed by transfecting the BTR reporter plasmids into A549 and 1833 cells using Fugene (Roche Diagnostics) and resulting clones were selected using 500 µg/ml (A549) or 250 µg/ml (1833) G418 (InVitrogen) containing media. Twenty-four stable clones were selected for both wild-type and mutant cell lines. The BTR-WT expressing clones were analyzed by bioluminescent imaging following treatment with 10 µM SB431542 (Cayman Chemical, Ann Arbor, MI). Single cell subclones were generated and maintained in 250 µg/ml G418 containing media.
Antibodies and Reagents
Rabbit polyclonal antibodies to phospho(S465/467)Smad2, Smad2, p(S423/425)Smad3, Smad6, TGFΒR1/ALK5, TGFΒRII, C-Myc, C-Jun, p(Y845)EGFR, EGFR, p(Y1248)HER2, p(T180/Y182)P38MAPK, P38MAPK, p(P85-Y458/P55-Y199)PI3-K, PI3-K, TGFBR1/ALK5 inhibitor SB431542, AG1296, Tyrphostin AG1478, and SP600125 were obtained from Cayman Chemical (Ann Arbor, MI); pan-RTK inhibitor PP2 from Calbiochem-EMD chemicals (Gibbstown, NY); and SB203580 (Invivogen, San Diego, CA). Lapatinib in tablet form (Tykerb) was purchased from the University of Michigan pharmacy. Erlotinib was a kind gift from Genentech (San Francisco, CA). D-Luciferin was purchased from Promega Corp.
(Madison, WI). An 84-compound kinase-specific library was obtained from Timtek Drug Discovery (Newark, DE). SBE4-Luc reporter plasmid (17) was a kind gift of Dr Bert Vogelstein (Addgene plasmid #16495).
Bioluminescence reporter assay and live-cell imaging
For the reporter assay, A549 and 1833 BTR cell lines were seeded in 96-well (5x10 
Small interfering RNA transfection analysis
TGFBR1 and TGFBR2 small interfering RNA (siRNA), an siGENOME Smart Pool, and nonsilencing siRNA (NSS) were synthesized by Dharmacon Research (Lafayette, CO).Knockdown experiments were performed by transfecting A549 and 1833 BTR-WT reporter cells with 100nM siRNA for TGFBR1 and TGFBR2, as well as for non-targeted siRNA (NSS) as a negative control using Dharmafect1 (Dharmacon Research, Lafayette, CO). The transfected cells were incubated for 60 h, serum starved overnight, and 10ng/ml TGFβ added 1 h prior to evaluating reporter activity with bioluminescent imaging and Western analysis. Fold change in reporter activity was calculated over change in activity in NSS treated cells.
Western analysis and immunoprecipitation
Western analysis was carried out using standard protocols. A549 and 1833 BTR cell lines were grown in culture dishes, treated with select compounds for designated time periods, and cell lysates resolved on SDS-PAGE gels and transferred to PVDF membranes. Membranes were probed against specific primary antibodies followed by HRP conjugated secondary antibodies then visualized using the Enhanced Chemiluminescence (ECL) Western Blotting System (GE Healthcare, Piscataway, NJ).
Immunoprecipitation of the BTR reporter molecule was carried out by incubating cell lysate (400µg protein) with 5µg luciferase specific antibody for 1 h. The immune complex was captured using 20µl slurry of protein A/G-coupled Sepharose beads (GE Healthcare) for 1 h, washed three times with RIPA buffer. The resulting pellet was resolved by SDS-PAGE and transferred to PVDF membrane for Western analysis.
To study the effect of various inhibitors on Smad2/3 complex formation with Smad4, coimmunoprecipiation was carried out using a Smad3 antibody. A549 cells were serum starved and treated with 10µM inhibitors in the presence of 10ng/ml TGFβ for 1hr. Lysates were made in native lysis buffer (50mM Tris PH 7.4, 1% NP40, 0.25% Deoxycholate sodium salt, 150mM 
In vivo bioluminescence imaging of mouse tumor models
Tumor xenografts expressing BTR-WT were established by implanting 2.5x10 In parallel, tumor xenografts were generated in mice using A549 BTR WT and MUT reporter expressing cells. Mice were treated as described and bioluminescence was measured 4hr after treatment. All mice experiments were approved by the University Committee on the Use and Care of Animals (UCUCA) of the University of Michigan.
Immunohistochemistry
Tumors from mice treated with SB431542 (10mg/kg) or vehicle, for 4 h, were excised and fixed in formalin. The tumors were processed at the UMCCC Tissue Core Facility and stained with anti-pSmad2 antibody (1:100); micrographs were taken using an Olympus microscope fitted with an Olympus DP-70 high resolution digital camera. Cell nuclei stained positive for pSmad2 were counted in three random fields for vehicle (n=3) and SB431542 (n=3) treated tumors. A two sided student's t-test was performed to assess statistical significance. Slides were adjusted for brightness and contrast with Adobe Photoshop CS2 (Adobe Inc., San Jose, CA) but the micrographs underwent no other manipulations.
Data analyses
Western blot signal intensity was measured using the image processing and analysis program, ImageJ v1.45 (18) . Pearson correlation coefficient (r) was estimated to confirm how well the SB431542 doses correlate to BTR reporter fold induction and pSmad2 levels. Analysis of 
Results
Construction and mechanism of the bioluminescent TGFβR1 reporter
The key step in TGFβ signaling is the phosphorylation of receptor-regulated Smads by active TGFΒR1 receptor. To study this essential step, we designed a bioluminescent TGFβR1 reporter using a split firefly luciferase construct (Fig. 1A) , consisting of the critical TGFβ substrate, the C-terminal SXS motif of Smad2, linked to the phospho-peptide-binding domain In addition to the wild-type reporter (BTR-WT), we constructed a BTR mutant (BTR-MUT) reporter based on reports that mutations of the SXS motif abolish Smad2 phosphorylation by TGFΒR1 (13) . The Smad2 C-terminal serine residues 465 and 467 were mutated to the neutral amino acid alanine (Fig. 1A) .
Increased BTR reporter activity following treatment with TGFβR1 inhibitor SB431542
To evaluate whether the BTR reporter provides a sensitive and robust response to inhibition of TGFβ-mediated Smad2 phosphorylation, we imaged A549 and 1833 BTR-WT cells following treatment with varied concentrations of SB431542 (21) (22) (23) (24) in the presence of 10ng/ml TGFβ.
Bioluminescence activity was measured sequentially for 6 hours revealing both concentrationand time-dependent increases in reporter activity, reaching peak luminescence within 60 minutes post-treatment (Fig. 1C, Suppli Fig. 2A ). The BTR reporter activity increased with greater concentrations of inhibitor, reaching a maximum expression of more than 10-fold with 25µM SB431542 in A549 ( of the BTR-WT reporter activity to TGFBR1 kinase phosphorylation of the Smad2 substrate.
These changes in BTR reporter activity were not the result of changes in levels of total Smad2 or reporter ( Fig. 1D, Suppli Fig. 2B-C) .
BTR reporter sensitivity to indirect inhibition of Smad2 phosphorylation
Studies have shown that active src-kinase is a downstream mediator of TGFβ-induced cellular responses (25) . To study the sensitivity of the BTR reporter assay to indirect effectors of Smad2 phosphorylation, we treated A549 BTR-WT cells with the src-kinase inhibitor, PP2 (26) , in the presence of 10ng/ml TGFβ. Inhibition of src-kinase activity results in both a concentration-and time-dependent increase in reporter response, with peak bioluminescence occurring approximately two hours post-treatment (Suppli. Fig. 1A ). Western blot analysis confirms that increase in reporter activity corresponds to decrease in pSmad2 levels, two hours post-PP2 treatment (Suppli. Similar to SB431542 treatment, these results were not due to any significant change in levels of total Smad2 (Suppli. Fig. 1B ).
In vitro A549 BTR-WT cellular responses to TGFβ stimulus
To monitor the effect of the biological transducer on BTR reporter activity, we treated A549 BTR-WT cells with 10ng/ml TGFβ, revealing a nearly 60% decrease in reporter activity at 1h post treatment, whereas treatment of A549 cells expressing the mutant reporter show minimal effect on reporter response ( Fig. 2A) . Western blot analysis of similarly treated A549 BTR-WT cells indicate a corresponding increase in pSmad2 at 15 minutes that remained at maximal levels for 2 h, followed by slightly lower levels at 4 and 6 hours (Fig. 2B) .
Verifying that TGFβ-induction phosphorylates the target peptide, the reporter molecule was immunoprecipitated from cell extracts with anti-luciferase antibody and immuno-blotted with a phospho-serine-specific antibody. The BTR protein had a substantial increase in phosphoserine levels following TGFβ treatment as compared to controls (Fig.2C, Suppli Fig. 2D ). Following treatment with SB431542, phosphoserine levels are significantly lower than control levels (Fig.   2C, Suppli Fig. 2D ) corresponding with increased BTR reporter activity as determined directly by bioluminescence imaging.
To further confirm the link between reporter activity and TGFβ signaling, we suppressed the expression of the upstream kinases by transiently transfecting A549 BTR-WT cells with TGFΒR1 and TGFΒR2 specific siRNA resulting in approximately 6-fold and 3-fold increases in reporter activity, respectively (Fig. 2D) . Cells transfected with non-target siRNA (NSS) did not affect reporter activity (Fig. 2D) . Similar observations were made in 1833 BTR WT cells which exhibited 2.5 fold increase in reporter activity with TGFBR1siRNA (Suppli Fig. 2E ) although no significant activation of the reporter was observed with siRNA to TGFBR2. Cell extracts prepared from parallel experiments and probed with antibodies against TGFΒR1 and TGFBR2 confirm the siRNA mediated suppression of these proteins. A substantial increase in pSmad2 was observed in NSS transfected TGFβ-treated cells while theTGFBR1 and TGFBR2 knockdown cells, with or without TGFβ stimulation, have minimal levels of pSmad2 (Fig. 2E,   Suppli Fig. 2F ) which closely correlates with reporter bioluminescence activity (Fig. 2D, Suppli   Fig. 2E ).
Research. 
To demonstrate that A549 BTR WT cells undergo epithelial-to-mesenchymal (EMT) transition
and exhibit the characteristic mesenchymal phenotype with TGFβ treatment (3, 27, 28), we treated serum starved cells with 10ng/ml TGFβ for up to 96 h and studied the changes in cell morphology every 24 h post-treatment. TGFβ treated cells lost cell-to-cell contact and exhibited characteristic elongated, spindle shaped morphology (Fig. 2F) . These samples were prepared for Western blot analysis and probed against epithelial marker E-cadherin, and mesenchymal marker N-cadherin. An increase in levels of N-cadherin and corresponding decrease of E-cadherin was observed ( Fig. 2G) which is a characteristic of cells undergoing EMT.
Two early regulatory genes shown to be downstream targets of R-Smad activation are the oncogenes c-jun and c-myc (29, 30) . Expression levels of c-myc decreased over 96 hours and c-jun levels increased during the same time period (Fig. 2G) . We further elucidated the connection of c-myc and c-jun expression to TGFβ signaling in A549 cells by treating with TGFβ alone and in the presence of SB431542. With TGFβ, c-myc levels remain constant for up to 6h but when TGFβ signaling was inhibited, c-myc levels increased (Fig. 2H) . Conversely, c-jun expression levels increase within 1 h after TGFβ treatment and are abolished in the presence of SB431542 (Fig. 2H) .
In vivo imaging and analysis of TGFβ signaling in BTR expressing tumor xenografts
Having established the specificity and sensitivity of the BTR reporter in vitro, we next investigated reporter utility for monitoring changes in TGFβ signaling in a tumor mouse model. hours post-treatment. Reporter activity remained elevated through 8 hours followed by lower, but sustained, reporter activity at 24 h (Fig. 3A-B) . Bioluminescence was unchanged over the 24-hour period in vehicle-treated mice (Fig. 3A and 3B) .
In a similar experiment mice (n=5) bearing xenografts of A549 BTR WT and MUT reporters were treated with 10 mg/kg SB431542 and DMSO control. Bioluminescence was acquired 4hr after treatment and plotted as fold change over control (Suppli . Fig 3) . BTR WT expressing tumors showed around 8 fold induction in bioluminescence activity with SB431542 while MUT tumors exhibited an attenuated response (around 3.5 fold).
Since BTR reporter bioluminescence represents decreased levels of pSmad2, we next evaluated pSmad2 levels in tumor xenografts harvested 4h post treatment when peak bioluminescence was observed. Immunohistological staining was performed using pSmad2 specific antibody ( Fig.   3C-D) . Total numbers of pSmad2 positive nuclei were counted for each group and plotted, revealing a significant decrease (p = 0.06) in levels of pSmad2 stained nuclei in SB431542 treated tumors (761 nuclei, 37.03%) as compared to control tumors (1294 nuclei, 62.97%), (Fig.   3D ).
High throughput screening of BTR reporter assay against a kinase-inhibitor compound library reveals crosstalk with multiple kinase signaling pathways Research. on confirming assay specificity for phosphorylation of the C-terminal SXS motif (Fig. 4A) .
Additionally, the HTS screen was repeated using the 1833 BTR WT reporter cell line, to independently validate the obtained hits (Fig. 4C) . Most of the hits between two cell lines were similar although the reporter fold induction varied (Fig. 4A and 4C, Table 1 ). The EGFR directed inhibitor AG1478 was a hit in A549 and 1833 cells (8.2 fold and 12.7 fold). Not surprisingly, the Akt inhibitor (BML257) and the PI3K inhibitor (LY294002) were also hits in the A549 cells (5.0 fold and 5.4 fold, respectively). In 1833 cells LY294002 yielded a 12.3 fold increase in bioluminescence, while BML257 yielded 3.1 fold increase. A JNK inhibitor (SP600125) and p38MAPK inhibitors (SB203580 and SB202190), important regulators of TGFβ signaling were also hits in both cell lines (see Table 1 ). Interestingly, GW5074 was a hit in 1833 cells but not in the A549 cells.
Research. To evaluate the effect of these inhibitors on TGFβ-induced Smad2 phosphorylation, select active compounds, along with two clinically important receptor kinase inhibitors, Erlotinib and Lapatinib, underwent further analysis. A549 BTR-WT cells were treated with inhibitors in the presence of TGFβ, lysates were prepared, and Western blots probed with pSmad2 antibodies.
The results (summarized in Table 1 To delineate other signaling events affecting TGFβ receptor activity we probed the Western blot with antibodies to target proteins (see Table 1 for references). The PTK inhibitors Erlotinib, Lapatinib, and Tyrphostin AG1478 reduce levels of pHER2 and pEGFR while increasing the expression of the inhibitory-Smad, Smad7. The Tyrphostin analog, AG825, had no measurable effect on activation of HER2 or EGFR kinase. AG825 is an ATP-competitive inhibitor of HER2
and EGFR kinase activity in cell-free assays but, due to high intracellular ATP levels, it has treatments with no corresponding decrease in GAPDH levels suggesting results are not due to differences in protein loading (Fig. 4B) .
Staurosporine treatment caused only a small increase in BTR activity and a moderate decrease in Smad2 phosphorylation while completely blocking activation of PI3K and causing a marked increase in p-p38 MAPK along with reduced expression of most of the other proteins measured including luciferase. It has been reported that Staurosporine treatment of Mv1Lu cells, 100ng/ml, increased pSmad2 and enhanced TGFβ-stimulated apoptosis (32) suggesting that a 5-hour exposure to a 10-fold higher concentration of Staurosporine, as seen in our experiment, most likely initiated cell death thus decreasing protein expression (Fig. 4B) . after 72 hour treatment of keloid fibroblasts (34) . In this study, quercetin treatment stimulated BTR reporter bioluminescence and showed a moderate inhibition of TGFBR1 and pEGFR levels but did not demonstrate any measureable inhibition of pSmad2 levels, PI3K signaling, or increased expression of inhibitory Smad7. These results suggest that the reporter response may be a result of an immeasurable change in pSmad2 level due to moderate changes in TGFBR1 and pEGFR expression (Fig. 4B) . Lysates were also probed with c-Jun and c-Myc antibodies to evaluate the effect of each inhibitor on TGFβ/Smad-mediated transcription.
Two RTK inhibitors which abrogated TGFβ-induced activation of Smad2 (Lapatinib and AG1478) were selected for further analysis. Lapatinib activated the BTR-WT reporter at a dose of 1µM (~4 fold), but failed to activate the mutant reporter significantly at doses as high as 10µM (Fig 5 A) . Tyrphostin AG1478 also activated the WT reporter similarly, and did not alter the activity of the MUT reporter substantially (Fig 5 A) . These data demonstrate that Lapatanib and AG1478 were valid hits in the screen.
To further evaluate the validity of the two RTK-inhibitors as modulators of TGFβ signaling, their impact on Smad2/3-Smad4 complex formation was evaluated. Formation of a Smad2/3-Smad4 complex is a critical event for nuclear translocation of Smad2/3. Lysates from A549 cells treated with SB431542, PP2, AG1478 and Lapatinib in the presence of TGFβ were immunoprecipitated using a Smad3 antibody and co-immunoprecipitation of Smad4 was evaluated (Fig 5C) . SB431542 and PP2 completely blocked Smad3-Smad4 complex formation compared to TGFβ treated cells, while AG1478 substantially and Lapatinib marginally blocked complex formation between Smad3-Smad4 in A549 cells. The reduced Smad complex formation was due to blockade of TGFβ-induced phosphorylation and activation of Smad2/3 as seen in the input lysates (Fig 5C) . Additionally to elucidate if inhibition of Smad2/3-4 complex formation by PP2 and RTK-inhibitors have any effect on downstream transcriptional responses mediated by TGFβ, we carried out transcriptional response assay using a TGFβ responsive reporter SBE4-Luc (17) (Fig 5D) . TGFβ strongly activated the SBE4-Luc reporter in A549 cells which was significantly blocked by the ALK5 inhibitor SB431542 and moderately blocked by PP2, AG1478 and Lapatinib. These results suggest that PP2, AG1478 and Lapatinib partially inhibit the activation of Smad pathway resulting in inhibition of TGFβ-induced transcriptional activity. 
Discussion
The dual modality of TGFβ, both as a potent tumor suppressor and a stimulator of tumor progression, invasion and metastasis, make it a critical target for therapeutic intervention in human cancers. The ability to perform real-time, non-invasive imaging of TGFβ-activated Smad signaling in live cells and animal models would significantly improve our ability to develop targeted therapeutics for cancer and to monitor their effects in vivo. To study TGFβ-mediated phosphorylation of the C-terminal serines of R-Smads, we constructed a TGFBR1 bioluminescent molecular imaging reporter, described in Figure 1A -B, based on split-luciferase technology (14) . We validated the specificity and responsiveness of the BTR reporter through direct inhibition of TGFBR1 kinase activity, and indirectly, through inhibition of src-kinase, a downstream modulator of TGFβ-stimulated Smad2 phosphorylation (25) . Reporter bioluminescence activity shows a robust response following inhibition of TGFBR1 kinase activity with SB431542. Time-and concentration-dependence of SB431542 inhibition of TGFBR1 kinase was confirmed by increased reporter activity and a concomitant decrease in levels of pSmad2 (Fig. 1C-E, Suppli. Fig. 2) .
The EC 50 derived using the reporter (for SB431542) was estimated to be 2.09 µM, while the pSmad2 westerns yielded an EC 50 of 1.6 µM in A549 cells. In 1833 cells, the values were 15.68 µM using the reporter and 0.36 µM using pSmad2 westerns. Strong positive correlation (Fig.   1C'; Suppli. Fig. 2A') , goodness of fit, and statistical significance between reporter fold induction and SB431542 concentration clearly demonstrate the robustness nature of the BTR reporter. A strong negative correlation between reporter fold induction and pSmad2 levels ( Fig.   1E; Suppli. Fig. 2B bottom panel) further substantiated the effectiveness of the reporter. BTR-WT cells ( Fig. 2A) and the corresponding increase in pSmad2 (Fig. 2B) . The sustained decrease in reporter activity and prolonged elevation of pSmad2 are consistent with continuous shuttling of Smad proteins between cell nucleus and cytoplasm shown to exist during TGFβ signaling (23) . Immunoprecipitation of the reporter, followed by analysis of phosphoserine content, confirms that the reporter was phosphorylated in a TGFβ-dependent manner ( Fig. 2C; Suppli. Fig. 2D ). In addition, suppression of the upstream kinases by siRNA knockdown of TGFΒR1 and TGFΒR2 verifies the direct link between reporter activity and TGFβ receptor signaling. Knockdown TGFBR1 and TGFBR2 cells have reduced levels of pSmad2 and show a significant increase in reporter bioluminescence ( Fig. 2D-E; Suppli. Fig. 2E-F) .
TGFβ signaling contributes to tumor progression and metastasis through activation of epithelial- elongated, spindle-shaped morphology (Fig. 2F) . Protein analysis reveals the characteristic EMT downregulation of E-cadherin expression, a critical caretaker of epithelial integrity, and a corresponding upregulation of N-cadherin (Fig. 2G) (35) . Activated Smad2 has also been shown to regulate expression of the proto-oncogenes c-myc (30) and c-jun (29) . TGFβ downregulation of c-myc is critical to growth inhibition (30) where the upregulation of c-jun is important for cell survival (29) . TGFβ stimulation of A549 BTR-WT cells suppresses c-myc expression with a corresponding upregulation of c-jun (Fig. 2G) . Cell treatment with TGFBR1 kinase inhibitor SB431542 results in increased expression of c-myc and eliminates c-jun expression (Fig. 2H) . Fig. 4) .
Research has shown growth factors which signal through receptor tyrosine kinases (RTKs) such as, hepatocyte growth factor (HGF) and epidermal growth factor (EGF), mediate Smad2 activity independent of TGFΒR1 activation, suggesting intricate crosstalk between RTK and RSK signaling pathways (37, 38 
epidermal growth factor receptor 2 (HER2) kinase inhibitors Erlotinib, Lapatinib, and Tyrphostin AG1478 block TGFβ-mediated increases in pSmad2 (Fig. 4B) . Lapatinib, and Tyrphostin AG1478 marginally reduce TGFβ-mediated phosphorylation of Smad3 while Erlotinib had no significant effect (Fig. 4B) .The reduction in pSmad2 levels coincides with an equally pronounced decrease in expression of the active kinases, phosphorylated HER2 (pHER2) and phosphorylated EGFR (pEGFR). Treatment of A549 BTR-WT cells with SB431542 also reduces basal levels of pEGFR, further supporting signaling crosstalk between RTK and RSK pathways.
An important component of crosstalk between TGFβ-and RTK-signaling is the increased expression of inhibitory-Smad (I-Smad) proteins (39) . The I-Smads, Smad6 and Smad7, modulate signaling of TGFβ and, another TGFβ isoform, bone morphogenetic protein (BMP) by binding to the activated Type-1 receptor thereby, preventing recruitment and phosphorylation of R-Smads (38, 39) . In some cell-types, TGFβ or BMP induce I-Smad expression resulting in a negative feedback mechanism to regulate further TGFβ-or BMP-signaling. Besides induction by TGFβ or BMP, I-Smad expression can also be induced in a cell-dependent manner by other cytokine signaling pathways and stress induction (39, 40) . In A549 cells, expression levels of Smad6 and Smad7 did not increase following TGFβ treatment. However, treatment with EGFR and HER2 kinase inhibitors significantly increased expression of Smad7 in A549 BTR-WT cells resulting in interference with recruitment and phosphorylation of Smad2 by active TGFΒR1 (Fig. 4B) . These data suggest that, at least in part, the RTK signaling pathways increase activation of R-Smads by suppressing Smad7 expression and subsequent interference with Erk/MEK (U0126), had no effect. These observations are supported by our screening results, BTR reporter activity was increased for inhibitors shown to reduce R-Smad activation (LY294002, SB203580, and SP600125) (Fig. 4A) and was inactive when treated with inhibitors to kinase pathways that do not modulate TGFβ-stimulated phosphorylation of C-terminal serines of Smad2/3 (PD98059, Ro31-8425, and U0126) (Data not shown). A parallel screen using the 1833 cell line stably expressing the BTR WT reporter yielded hits that were overlapping with the hits obtained from the A549 cells (Fig 4C) . Published studies support some of these hits, for example, inhibitors for JNK (SP600125), and p38 MAPK (SB203580) have been shown to downregulate phosphorylation of the C-terminal serines in rat mesangial cells (42) and the p38 MAPK inhibitor (SB202190) abolishes TGFβ-activation of Smad-dependent promoters and attenuate pSmad2 levels in glioblastoma cells (43) .
However, the extent of signaling crosstalk between TGFβ and MAPK pathways has been shown to be dependent on cell-type and cell-context. Where the previous studies demonstrate JNK and (Fig. 4A-B) . Inhibition of Akt1/2/3, a PI3K target protein, with BML257 also activates the BTR reporter but did not yield a measurable decrease in pSmad. PI3K signaling has been shown to be critical for Smad2-dependent activity in fibroblasts (41) and transcriptional responses, EMT and cell migration of NMuMG cells (47) .
Although C-terminal SXS phosphorylation by the TGFβ type-1 receptor is the key event in
TGFβ-signaling, phosphorylation of the linker region and, to a lesser extent, the MH1 domain of Smad proteins by intracellular protein kinases can also positively and negatively regulate R-Smad activity (2) . Inhibitors for many of these kinases were screened with the BTR reporter 
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Erlotinib n/a n/a n/a 0.6 EGFR tyrosine kinase (37) Lapatinib n/a n/a n/a 0.0 EGFR and Her-2 tyrosine kinase (37)
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